2019•Int Rev OphthalmolRequires access
Treatment of age-related macular degeneration and polypoidal choroidal vasculopathy by Aflibercept
Min Qi, Jun Kong
Open publisher page 0 citations
Abstract
Aflibercept is a fully humanized recombinant fusion protein that blocks all subtypes of vascular endothelial growth factor (VEGF)-A and placental growth factor (PLGF) in the VEGF family. A number of large clinical trials have confirmed the efficacy and safety of aflibercept in the treatment of age-related macular degeneration (AMD) and polypoidal choroidal vasculopathys (PCV) as well as in the treatment of AMD and PCV which are resistant to ranibizumab. Compared with other anti-VEGF drugs, such as pegaptanib, ranibizumab and bevacizumab, aflibercept, which is a new generation of anti-VEGF drug, has a wider target, stronger affinity and longer action time. Therefore, it can reduce the frequency of drug administration, the adverse effect caused by the repeated injection, and the economic burden of patients without reducing the curative effects. (Int Rev Ophthalmol, 2019, 43: 355-359)
Key words:
aflibercept; vascular endothelial growth factor; age-related macular degeneration; polypoidal choroidal vasculopathy